Recent studies by Campesato et al. (2015) [21] and Rosenberg et al. (2016) [14] demonstrated that comprehensive cancer-gene panels can be used to estimate mutational burden and predict clinical benefit to PD-1 blockade in clinical practice. The gene discussed is PDCD1; the disease is cancer.